RecruitingPulmonary Embolism
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
Eligible age
18+ yrs
Accepts
All genders
Locations
25 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
Sponsor: Penumbra Inc.
You may qualify if…
- ✓ 1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less
- ✓ 2. RV/LV ratio ≥ 0.9 assessed by diagnostic computed tomographic angiography (CTA) or echocardiogram
- ✓ 3. Frontline endovascular treatment with the Indigo Aspiration System per IFU
- ✓ 4. Patient is ≥ 18 years of age
- ✓ 5. Informed consent obtained per Institutional Review Board/Ethics Committee requirements
You may not qualify if…
- ✕ 1. Contraindication to systemic or therapeutic doses of anticoagulants (e.g. heparin)
- ✕ 2. Stage IV (metastatic) cancer, active lung cancer or previous history of surgery in the affected lung(s) or chest radiation
- ✕ 3. Known serious, uncontrolled sensitivity to radiographic agents
- ✕ 4. Life expectancy \< 180 days
- ✕ 5. Patients on ECMO
- ✕ 6. Pregnant patients
- ✕ 7. Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies
- ✕ 8. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
Where it's recruiting
California
Long Beach · Los Angeles · Orange · San Diego
Delaware
Newark
District of Columbia
Washington D.C.
Florida
Bradenton · Brandenton · Delray Beach · Gainesville …
Georgia
Augusta
Illinois
Belleville · Glenview · Maywood
Kansas
Kansas City
Louisiana
Shreveport
Massachusetts
Boston · Fall River
Michigan
Detroit
Minnesota
Minneapolis
Mississippi
Jackson
Source: ClinicalTrials.gov · NCT04798261 · last updated 2026-07-06